 Continuous infusion alpha interferon advanced cancers report initial treatment results Twenty-four patients advanced metastatic cancer continuous intravenous infusion interferon units times week average duration treatment days days planned time treatment patients average interferon injections Objective tumor responses untreated patients Twenty-two patients toxicity equal ECOG II treatment interruption subsequent dose reduction following reasons mucositis hand-foot syndrome leukopenia incidence treatment toxicity infusion true augmentation effect interferon infusion alpha interferon useful combination evaluation future phase II phase III trials